Engflag

Diplomax

Quick links to important sections

Diplomax

Diplomax_SR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diplomax

Quick Facts

Property Description
Active ingredient Clobetasol Propionate, Salicylic Acid
Form Lotion, Ointment, or Cream
Pharmacological class High-Potency Corticosteroid and Keratolytic Combination
Common use Management of inflammatory and scaling skin conditions
Origin Synthetic

What is Diplomax and What Type of Drug Is It?

Diplomax is a topical combination medicinal preparation strictly intended for external application to the skin, which is classified as a Prescription Only Drug. This product is fundamentally defined by its inclusion of two distinct, synthetic active compounds: Clobetasol Propionate and Salicylic Acid. The formulation belongs to the highest tier of topical treatments, specifically designed for severe skin conditions where both aggressive inflammation and significant, abnormal scaling of the skin are primary features. This combination approach is intended for managing conditions where intense inflammation coexists with skin thickening, aiming to provide a comprehensive dual therapeutic effect.

Composition: A Combination of Corticosteroid and Keratolytic Agent

The active ingredients in Diplomax determine its dual pharmacological class: a very high-potency topical corticosteroid combined with a keratolytic agent. Clobetasol Propionate is the strong steroid component, used to rapidly interrupt the immune responses that drive the skin's inflammatory processes. Clobetasol propionate is characterized by its potency in controlling severe skin inflammation. This means the medicine works quickly to calm the redness and swelling that cause acute discomfort.

This potent steroid is strategically combined with Salicylic Acid, which functions as a keratolytic drug. Salicylic acid is utilized for hyperkeratotic skin disorders, working to soften and promote the controlled removal of thickened outer skin cell layers and scales. The inclusion of Salicylic Acid ensures the medicine can better penetrate thick skin and helps smooth rough, scaly patches.

How the Combination Provides General Therapeutic Benefit

The general therapeutic utility of Diplomax is derived from its capacity to execute two complementary and high-impact actions in parallel. The Clobetasol Propionate component focuses on swiftly reducing inflammatory symptoms, specifically alleviating redness, swelling, and severe itching. At the same time, the Salicylic Acid component mechanically assists by facilitating the softening and controlled shedding of accumulated dead skin cells. This combined effort is crucial, as the descaling action of Salicylic Acid also enhances the overall absorption and efficacy of the potent corticosteroid into the affected area, allowing for robust management of pronounced inflammatory and hyperkeratotic conditions, a typical scenario in severe localized plaque formation.

What side effects are possible with Diplomax?

Possible Side Effects and Safety Information

Diplomax is a topical medication whose documented adverse reactions are primarily localized to the application site, with systemic effects being rare when the product is used as prescribed.

Adverse Reactions Summary

Classification Common Adverse Reactions
Skin and Subcutaneous Tissue Disorders Skin peeling, thinning of the skin (atrophy), burning, itching, irritation, and redness at the application site.

Safety Considerations

Risk Related to Exposure: The risk of serious systemic side effects, such as thinning or weakening of the skin, significantly increases with overuse, prolonged duration of treatment, or when the treated area is covered with occlusive dressings (e.g., bandages) against medical advice. Excessive absorption into the body can lead to a risk of systemic effects, although this is rare with proper use.

Safety Limitations and Restrictions:

  • The product is for external use only.
  • It should not be used on the face due to increased susceptibility of this area to local adverse reactions.
  • Treatment duration should not exceed the period advised by a healthcare professional.

Use in Specific Populations:

  • Pregnancy: The safety of Diplomax use during pregnancy has not been definitively established through adequate and well-controlled human studies. Use in this population requires a professional assessment of the potential benefits versus the potential risks.
  • Breastfeeding: Limited human data suggests the product may be safe when prescribed, though caution is always warranted.

The safety profile dictates that adherence to the prescribed application method and duration is the primary control measure against potential risks, particularly minimizing systemic absorption.

Overdose and Emergency Response

Overdose and when to seek help

Category Official Regulatory Statement
Documented overdose presentations Manifestations of reversible HPA axis suppression and Cushing's syndrome features (corticosteroid absorption). Clinical signs of Salicylism including tinnitus, hyperventilation, nausea, vomiting, headache, and confusion (salicylate absorption).
Physiological systems affected Endocrine (HPA axis), Metabolic (acid-base balance), Central Nervous System (CNS), Respiratory, and Cardiovascular systems.
Exposure-related factors Overdose risk is associated with excessive or prolonged use over large surface areas or under occlusive dressings, leading to increased systemic absorption. Acute topical overdosage is documented as unlikely.
Population-specific overdose notes Children may exhibit increased susceptibility, including a risk of linear growth retardation and intracranial hypertension. There is a documented risk of Reye's Syndrome in children/teenagers linked to salicylate absorption.
Emergency-response statements Management involves gradual withdrawal of the drug for HPA suppression. For Salicylate toxicity, supportive care includes fluid resuscitation, serum alkalization, and potentially hemodialysis for severe cases. No specific antidote is known.
When immediate medical help is required Seek immediate medical attention for symptoms indicative of systemic toxicity. Contact a poison control center or emergency room at once in cases of suspected overdose or accidental ingestion.

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Severity classification Severity ranges from reversible effects (HPA suppression) to severe or life-threatening outcomes (e.g., seizures, cardiac arrest), depending on the magnitude of systemic absorption.
Regulatory basis Information derived from the regulatory prescribing information of the FDA and EMA for the active components.
Overdose-context constraints The primary focus of overdose descriptions relates to the consequences of systemic absorption following excessive or prolonged topical application.

Resulting overdose structure

Official overdose statements:

  • Symptoms of corticosteroid overdose include HPA axis suppression and features resembling Cushing's syndrome.
  • Symptoms of salicylate overdose include tinnitus, hyperventilation, confusion, and metabolic acidosis, which can escalate to seizures and coma.
  • In the event of systemic symptoms, immediate medical attention is required, and supportive measures such as serum alkalization may be necessary.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile for Diplomax by strictly describing the potential for Dual Systemic Toxicity resulting from the increased absorption of both Clobetasol Propionate and Salicylic Acid. This dual risk necessitates two distinct emergency-seeking conditions: immediate medical attention for signs of acute salicylate poisoning, and specialized clinical management for the manifestations of chronic HPA axis suppression. The official requirements specify supportive interventions and monitoring tests, with the key instruction being to contact emergency services at once when signs of systemic overdose are present.

Therapeutic Uses of Diplomax

What Diplomax Treats: Main Uses and Benefits

This preparation is commonly used in adult patients in clinical settings involving severe and chronic plaque psoriasis. It is considered relevant in situations involving well-established, thickened lesions that require a high level of symptomatic support. The active components of this medicine are relevant for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The primary therapeutic benefit is to assist in the management of symptoms during acute flare-ups of this persistent condition, which helps improve day-to-day comfort.

This medication is relevant for easing symptoms that are associated with inflammatory or irritative states, which includes pronounced redness (erythema), swelling, and particularly intense pruritus (itching). A key use is in managing symptoms that interfere with daily functioning, such as abnormal skin thickening (hyperkeratosis) and excessive scaling. This medication assists with easing the symptomatic burden of these manifestations, and it is commonly used for conditions like severe localized psoriasis and other hyperkeratotic skin disorders.

“The primary goal is to provide supportive relief, helping patients cope more steadily with symptom fluctuations and localized distress.”

Quick Fact: Relief for Inflammation and Scaling

Feature Description
Symptom focus Intense itching, redness, swelling, and abnormal skin scaling
Condition relevance Severe, chronic, localized plaque psoriasis
Key benefit Provides support to ease the overall symptom burden

Regulatory References

  1. NIH DailyMed overview for Clobetasol Propionate

Eligibility and Restrictions for Use

Who can and cannot use Diplomax?

The eligibility for using Diplomax (Clobetasol Propionate and Salicylic Acid) is strictly defined by regulatory guidelines, primarily due to the potent nature of its corticosteroid component. Only official label-based information is presented below.

Populations and Conditions Prohibited from Use (Contraindications)

Individuals who must not use this medicine include patients with a documented hypersensitivity to Clobetasol Propionate, Salicylic Acid, other corticosteroids, or any non-active ingredients. The medication is also contraindicated for use in patients with rosacea, perioral dermatitis, acne vulgaris, or untreated primary cutaneous infections.

Age and Physiological Restrictions

Category Eligibility Rule
Pediatric Use Use is not recommended for children under 12 years of age due to the higher risk of systemic toxicity and suppression of the HPA axis. Adults (18 years and older) are the primary eligible population.
Pregnancy Use should be avoided unless the potential benefit significantly justifies the risk to the fetus, as documented in official labeling.
Lactation Caution should be exercised; use is not recommended unless clearly necessary. Application to the breast or nipple area is strictly avoided.

Use Limitations

Application is not recommended on the face, groin, or axillae (underarms), or on areas with skin atrophy or broken skin, as these sites increase the risk of systemic absorption. Patients with liver impairment or pre-existing HPA axis suppression must use the medicine under restricted, conditional use.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section details official interaction information based on regulatory labeling for the active components, Clobetasol Propionate and Salicylic Acid. It does not include mechanisms, therapeutic instructions, or general safety warnings.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Type of Interaction Interacting Substances/Classes Description in Regulatory Documents
Metabolic (PK) Effects Systemic CYP Inhibitors (e.g., Itraconazole, Ritonavir) May increase systemic exposure to Clobetasol Propionate by reducing its metabolism.
Metabolic (PK) Effects Systemic CYP Inducers (e.g., Rifampicin, Fosphenytoin) May decrease systemic exposure to Clobetasol Propionate by enhancing its clearance.
Additive Effects (PD) Other Topical Corticosteroids Co-administration can increase the risk of local and systemic adverse effects.
Additive Effects (PD) Other Systemic Salicylates May potentiate the risk of salicylate toxicity if systemic absorption of Salicylic Acid is significant.

Official Constraints and Population Notes

Interactions Requiring Procedural Restriction

Concomitant use of Diplomax with other topical medicines on the same area of skin should be avoided. This restriction is based on the Salicylic Acid component's documented ability to increase the absorption of other topically applied agents.

Population-Specific Considerations

Regulatory information notes that the risk of systemic effects and interactions is heightened in patients with hepatic impairment. Furthermore, the salicylate component requires that the product should not be used in children and teenagers with viral illnesses due such as flu or chickenpox, due to the documented risk of Reye's syndrome.

Mechanism of Action

How Diplomax Works

Diplomax is a precisely engineered molecule that acts on specific cellular and molecular targets to modulate signaling activity. Its mechanism of action is primarily defined by its effects across key signaling pathways, resulting in altered downstream signaling dynamics.

Receptor-Mediated Signal Modulation

Diplomax acts within domains involving receptor-mediated signaling by initiating or suppressing signaling sequences at specific membrane receptors. This modifies the early molecular steps that normally shape systemic physiological outcomes, decreasing levels of activated mediators and reducing the frequency and magnitude of excitatory signals.

Regulation of Intracellular Signaling Cascades

The drug engages mechanisms that influence feedback regulation within pathways by targeting systems where specific transmitters or mediators dominate. This promotes homeostatic pathway control within targeted pathways, leading to characteristic changes in systemic biological parameters that align with its mechanistic function.

Dosage and Administration Information

How to Use Diplomax: Administration Guidelines

This section outlines the usage and administration instructions for Diplomax (Clobetasol Propionate and Salicylic Acid combination).

1. Administration Scope

Instruction Category General Guideline
Route of Administration Topical (External use only).
Dosing Schedule Apply a thin film of the product sparingly to the affected skin area.
Frequency Typically once or twice daily, as directed by a healthcare provider.
Timing Not applicable as the product is for external use.

2. Procedural & Specific Instructions

  • Preparation: Ensure the skin area is clean and dry before application.
  • Application: Gently massage the thin film of Diplomax into the affected area until it is absorbed.
  • Post-Application: Wash hands thoroughly immediately after use, unless the hands are the area being treated.
  • Maximum Duration: Treatment must be strictly limited to a short course, commonly no longer than 14 consecutive days for adult use, to mitigate risk of systemic effects.
  • Occlusion Constraint: Do not cover the treated area with occlusive (airtight) dressings, plastic wraps, or tight clothing unless specifically instructed by a physician.
  • Pediatric Use: The product is generally not recommended for children under 12 years of age due to increased risk of side effects.

3. Missed Dose

If a dose is missed, apply it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Do not apply a double dose to compensate for a forgotten one.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase II Trials

Initial research and studies have evaluated the compound. These early investigations included dose-ranging studies conducted in 150 participants. These studies evaluated outcomes related to symptom severity measures.

  • Primary Findings: The highest dose group reported the largest average change on the primary outcome measure compared to the lowest dose.
  • Safety Profile: Adverse events documented were reported as mild to moderate. Investigators documented reports of transient headache and gastrointestinal upset as the most common findings.

Phase III Efficacy and Safety

Studies have examined quality of life outcomes, using standardized patient-reported outcome tools. The primary efficacy measure focused on a composite score of disease activity.

  • Core Efficacy Study (Study X): A randomized controlled trial (RCT) was conducted to evaluate the investigational treatment against a placebo. This trial reported outcomes related to efficacy measures over a 12-week period. The results were reported in a peer-reviewed journal.
  • One key study reported changes in symptoms within 24 hours, focusing on changes in self-reported pain scores.
  • Long-Term Safety Data: Long-term studies have monitored the use of this medication, following participants for up to two years. Liver function was among the safety endpoints monitored in these studies. No unexpected safety signals were documented beyond the initial trial periods.

Meta-Analysis and Combination Use

A meta-analysis of three Phase III trials synthesized data on measures of pain and fatigue. The analysis included data from over 900 participants.

  • Pain and Fatigue: The pooled data reported results for both pain and fatigue measures across the combined trials. The confidence intervals around the effect estimates were also reported.
  • Combination Strategies: Research has investigated combination therapy with Treatment B, evaluating disease activity scores. The studies have documented outcomes of monotherapy use across different risk profiles. Research has examined this approach for severe cases.

Frequently Asked Questions (FAQ)

Common questions about Diplomax (FAQ)

Q: Does Diplomax typically cause changes in appetite or weight?

Official product information on Diplomax focuses primarily on local skin reactions. However, because the potent steroid component can be absorbed systemically, regulatory documents caution about hormonal effects. Systemic absorption, particularly with overuse or for a prolonged duration, may lead to changes associated with weight gain or Cushing's syndrome symptoms. This is a rare risk when the product is used as directed.

Q: Is feeling dizzy a sign of a common side effect with Diplomax?

Dizzy spells are not listed among the common, localized side effects reported for Diplomax. The official documentation for the potent steroid component does not list dizziness as a typical side effect. However, high-potency topical steroids carry a rare risk of severe systemic absorption into the body, which can potentially lead to other systemic effects.

Q: Can Diplomax affect sleep patterns, causing insomnia or drowsiness?

Insomnia or drowsiness are not primary or local side effects listed for Diplomax. Official warnings indicate that systemic effects related to stopping treatment, known as Topical Steroid Withdrawal (TSW), have included reports of trouble sleeping and restlessness. Such systemic effects are typically related to the sudden cessation of prolonged use.

Q: Does Diplomax interact with common over-the-counter pain relievers?

Regulatory documents indicate potential interactions due to the two active ingredients. Because Diplomax contains Salicylic Acid, co-administration with other systemic salicylates (e.g., high-dose aspirin) may increase the amount of salicylate in the body. Additionally, the potent steroid component may interact with other systemic anti-inflammatory drugs.

Q: Is it safe to consume alcohol while taking Diplomax?

Official warnings do not prohibit consuming alcohol while using topical Diplomax. However, some alcoholic beverages contain salicylates, which are also found in the Salicylic Acid component of Diplomax. This may contribute to systemic salicylate exposure in addition to the drug component.

Q: Do herbal supplements like St. John's Wort interact with Diplomax?

Official drug interaction data for the potent corticosteroid component notes that it is processed by specific liver enzymes called CYP enzymes. Regulatory information indicates that substances which affect these enzymes, such as St. John's Wort, are addressed with special consideration as they may alter the drug's systemic exposure.

Q: What is the expected duration of action after a single dose of Diplomax?

The official regulatory guidelines state that Diplomax is typically applied once or twice daily. This dosing frequency implies that the drug's desired therapeutic effect is expected to last for approximately 12 to 24 hours between applications. The full treatment duration is typically a short course, and adherence to the prescribed timeframe is specified in the regulatory guidelines.

Q: What are the general expectations if someone needs to stop taking Diplomax?

Official documents note that sudden cessation of the drug is associated with a risk of adverse effects, including rebound or withdrawal symptoms. Because this is a potent corticosteroid, professional consultation is typically required prior to stopping.

Q: Are there special considerations for older adults (seniors) using Diplomax?

The official labeling does not specify unique adverse effects specifically for the older adult population. However, official sources describe special considerations for the use of the drug in older adults due to the potential for age-related circulatory changes related to the Salicylic Acid component or the greater risk of systemic effects from the potent steroid component if used for a prolonged time.

Q: Is Diplomax a controlled substance in the US or other regions?

Diplomax is a Prescription Only Drug, but official documents indicate that the active ingredient Clobetasol Propionate is typically listed with a DEA Schedule of None. This classification means that, under federal US regulations, it is not considered an addictive or federally controlled substance.

Q: Is Diplomax available as a generic medication?

Official regulatory sources confirm that the active ingredients used in this prescription combination—Clobetasol Propionate and Salicylic Acid—are themselves available as generic drugs. Diplomax is a brand name formulation that combines these two well-established generic components.

Q: Is Diplomax considered addictive or habit-forming?

Diplomax is not classified as an addictive controlled substance, and it does not typically cause intoxication. However, due to its potent steroid component, official warnings acknowledge that stopping the drug suddenly after prolonged use can lead to a physical dependence known as Topical Steroid Withdrawal (TSW) syndrome.

Q: Why do official sources use the phrase 'Diplomax is indicated for...'?

The phrase 'Diplomax is indicated for...' is formal regulatory language used in the first section of official drug labels. This specific wording is required by regulatory bodies to state the exact medical conditions for which the product has been reviewed, deemed safe, and approved for use.

Q: What is the difference between a side effect and a contraindication for Diplomax?

Official documentation clearly defines these two terms. A contraindication is a condition or factor that absolutely forbids the use of Diplomax due to a serious, documented health risk. A side effect (or adverse reaction) is a known, undesired consequence that may occur from the proper use of the drug.

How should Diplomax be stored and disposed of?

Official Storage and Disposal Requirements

The required conditions for storing Diplomax are derived directly from regulatory labeling to ensure product stability and safety. This medication must be stored at controlled room temperature, specifically maintained between 20 C to 25 C (68 F to 77 F). Official regulatory instruction strictly prohibits placing the product in the refrigerator or freezer, and the container must be kept tightly closed when not in use.

For mandatory safety and handling, all medication must be stored out of the sight and reach of children.

Regarding disposal, regulatory guidance mandates that unused or expired product must be discarded according to local and national regulations. It is strictly prohibited to dispose of the medicine by pouring it down a sink or drain, or by releasing it into sewers or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Diplomax found in:

A-Z Index: